Literature DB >> 7697946

Association between the oxidative polymorphism and early onset of Parkinson's disease.

J A Agúndez1, F J Jiménez-Jiménez, A Luengo, M L Bernal, J A Molina, L Ayuso, A Vázquez, J Parra, J Duarte, F Coria.   

Abstract

The frequency of five cytochrome P450IID6 allelic variants was studied in deoxyribonucleic acid from 123 patients with Parkinson's disease and 150 healthy volunteers. This was achieved by the use of mutation-specific polymerase chain reaction and restriction fragment length polymorphism. The analyses of the CYP2D6 genotype revealed no evidence for a higher prevalence of poor metabolizers among patients with Parkinson's disease. However, increased frequency of patients with Parkinson's disease with the genotype CYP2D6wt/CYP2D6B was observed. This is attributable exclusively to subjects with early onset of the disease (28 to 49 years), with a relative risk ratio of 4.16 (95% confidence limits, 2.0 to 8.3; p < 0.0005). The subjects who had late-onset Parkinson's disease (> or = 50 years) had genotypes and CYP2D6 allele frequencies similar to the healthy subjects. This indicates that the oxidative polymorphism is related to early-onset but not to late-onset Parkinson's disease. A different influence of CYP2D6 genotype on the risk of development of Parkinson's disease is observed in Spaniards, compared with previous findings in British subjects. These results suggest the combined effect of environmental toxins and CYP2D6 in the cause of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697946     DOI: 10.1016/0009-9236(95)90154-X

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

3.  The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease.

Authors:  T Gasser; B Müller-Myhsok; A Supala; E Zimmer; G Wieditz; Z K Wszolek; P Vieregge; V Bonifati; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

4.  Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?

Authors:  K Wilhelmsen; D Mirel; K Marder; M Bernstein; A Naini; S M Leal; L J Cote; M X Tang; G Freyer; J Graziano; R Mayeux
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

5.  Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease.

Authors:  José A G Agúndez; Antonio Luengo; Oscar Herráez; Carmen Martínez; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez; Elena García-Martín
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

6.  Cytochrome P450 1B1 mRNA in the human central nervous system.

Authors:  C R Rieder; D B Ramsden; A C Williams
Journal:  Mol Pathol       Date:  1998-06

Review 7.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Acetaldehyde and parkinsonism: role of CYP450 2E1.

Authors:  Francesca Vaglini; Cristina Viaggi; Valentina Piro; Carla Pardini; Claudio Gerace; Marco Scarselli; Giovanni Umberto Corsini
Journal:  Front Behav Neurosci       Date:  2013-06-21       Impact factor: 3.558

9.  Further evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control study.

Authors:  Muhammad Aslam; Nafees Ahmad; Jakob von Engelhardt; Mazhar Badshah; Rashda Abbasi; Aneesa Sultan; Kafaitullah Khan
Journal:  Genes Environ       Date:  2017-07-01

10.  CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis.

Authors:  Yu Lu; Cuiju Mo; Zhiyu Zeng; Siyuan Chen; Yantong Xie; Qiliu Peng; Yu He; Yan Deng; Jian Wang; Li Xie; Jie Zeng; Shan Li; Xue Qin
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.